Cisplatin, carboplatin shortages raise questions about impact on clinical trials 

At least two small biotechs have halted clinical trials due to shortages of cisplatin and carboplatin amid ongoing supply issues for the chemotherapies commonly used in cancer care.

Earlier this month, Replimune told investors that it put a Phase II clinical trial on hold until supply of both drugs becomes…
Click here to view original post

ADVERTISEMENT — Advertise With Biotech Networks